Amcor's Q2 FY2026 results were in line with guidance, showing resilience despite a challenging market. The company reiterated its full-year guidance, driven by cost controls and accelerating synergies from the Berry acquisition. Management focused on a solid integration execution and strategic portfolio optimization, notably for its non-core North American beverage business. Adjusted EPS for Q2 FY2026 was $0.86, up 7% year-over-year, including a one-time tax benefit. Total company volumes declined 2.5%, a slight sequential improvement.
Amcor's Q2 FY2026 results were in line with guidance, showing resilience despite a challenging market. The company reiterated its full-year guidance, driven by cost controls and accelerating synergies from the Berry acquisition. Management focused on a solid integration execution and strategic portfolio optimization, notably for its non-core North American beverage business. Adjusted EPS for Q2 FY2026 was $0.86, up 7% year-over-year, including a one-time tax benefit. Total company volumes declined 2.5%, a slight sequential improvement.
Amcor's Q2 FY2026 results were in line with guidance, showing resilience despite a challenging market. The company reiterated its full-year guidance, driven by cost controls and accelerating synergies from the Berry acquisition. Management focused on a solid integration…
Adjusted EPS for Q2 FY2026 was $0.86, up 7% year-over-year, including a one-time tax benefit. Total company volumes declined 2.5%, a slight sequential improvement.
Management repeatedly emphasized strong execution, synergy acceleration, and reaffirmed guidance, projecting confidence despite market headwinds.
The company reaffirmed its FY2026 guidance for adjusted EPS of $4.00-$4.15 and FCF of $1.8-$1.9B, expecting stronger second-half performance driven by seasonality, a step-up in synergies, and recovery in non-core businesses.
Core volume decline of 1.5% with focus markets outperforming. Management repeatedly emphasized strong execution, synergy acceleration, and reaffirmed guidance, projecting confidence despite market headwinds.
Management repeatedly emphasized strong execution, synergy acceleration, and reaffirmed guidance, projecting confidence despite market headwinds.
“Annualized sales revenue from business wins directly linked to our combination with Berry now exceeds $100 million, a strong start to our original three-year target of $280 million.”
“Adding another example of those we discussed last quarter, our strength and supply chain and multi-format capabilities have enabled us to support a major global pharmaceutical customer as they launch the solid oral dose GLP-1 therapy drug.”
“As we look to the second half, as PK mentioned, new contractual terms, better pricing, good operating environment, we should operate EBITs back into more traditional levels, which is more in the 7%, 8% range”
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Capex | FY2026 | $0.85B–$0.9B | $0.875B | MAINTAINED |
| EPS | FY2026 | $4.00–$4.15 | $4.08 | MAINTAINED |
| EPS | FY2026 Q3 | $0.90–$1.00 | $0.95 | GUIDED |
| Free cash flow | FY2026 | $1.8B–$1.9B | $1.85B | MAINTAINED |
| Дата прогноза | Показатель | Целевой период | Прогноз | Факт | Результат |
|---|---|---|---|---|---|
| FY2026 Q4 | EPS | FY2026 Q2 | $1.80–$1.90 | $0.86 | Missed |
Berry Acquisition integration is on track, with synergies accelerating to $55M in Q2 and total $93M in H1 2026, and management now has over $100M in annualized revenue wins directly attributable to the combination, nearly half of the original three-year target of $280M already locked in. — This indicates strong early execution on the M&A thesis, potentially derisking the deal's long-term value creation for shareholders.
… synergies with approximately 20 site closures or restructures approved or announced. These synergies, as expected, will primarily materialize in years two and three of our synergy realization timeline. Growth synergies have also been strong. We're gaining momentum as customers validate the value we bring through our expanded footprint and integrated product offerings to meet complete and complex packaging needs. Annualized sales revenue from business wins directly linked to our combination with Berry now exceeds $100 million, a strong start to our original three-year target of $280 million. We expect delivery against these wins will commence in the second half of fiscal 2026. Adding another example of those we discussed last quarter, our strength and supply chain and multi-format capabilities have enabled us to support a major global pharmaceutical customer as they launch the solid oral dose GLP-1 therapy drug. This is an exciting win that will benefit both segments through supply of blister packaging in Europe and rigid containers in the U.S. Overall, our teams are executing well against our proven integration playbook. We also remain confident in our ability to …
Amcor has won a significant supply contract for a major global pharmaceutical customer's new oral GLP-1 therapy drug, supplying blister packaging in Europe and rigid containers in the US. — This signals a shift in the GLP-1 drug delivery market towards oral formats and indicates Amcor is capturing new demand, potentially benefiting from the secular growth trend even as it may be a headwind for other parts of its portfolio.
… the value we bring through our expanded footprint and integrated product offerings to meet complete and complex packaging needs. Annualized sales revenue from business wins directly linked to our combination with Berry now exceeds $100 million, a strong start to our original three-year target of $280 million. We expect delivery against these wins will commence in the second half of fiscal 2026. Adding another example of those we discussed last quarter, our strength and supply chain and multi-format capabilities have enabled us to support a major global pharmaceutical customer as they launch the solid oral dose GLP-1 therapy drug. This is an exciting win that will benefit both segments through supply of blister packaging in Europe and rigid containers in the U.S. Overall, our teams are executing well against our proven integration playbook. We also remain confident in our ability to deliver at least $260 million of synergies in fiscal 2026, and a total of $650 million of synergies through fiscal 2028. Before turning the call over, I'd like to take a moment to formally welcome Steve Schroeder, who joined us as Amcor's CFO nearly three months ago. Steve has spent his early days …